People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Revalesio Corp | — | Pharmaceuticals | Series B | $103.4M | $624.1M | 2022 |
TOM BUMOL at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside TOM BUMOL on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Smith | 1 | 11 |
| Lee Huntsman | 1 | 5 |
| Scott Walchek | 1 | 4 |
| TROY ALSTEAD | 1 | 2 |
| Eric Russell | 1 | 2 |
| JANE TAYLOR | 1 | 2 |
| CHRIS FIBIGER | 1 | 2 |
| BRUCE BUSKIRK | 1 | 1 |
| JAMES NORDSTROM | 1 | 1 |
| MATT IRELAND | 1 | 1 |
| WILLIAM GALLACHER | 1 | 1 |
| LIAM GALLACHER | 1 | 1 |
| JIM NORDSTROM | 1 | 1 |
| Marsha Russell | 1 | 1 |
| Karl Bandlien | 1 | 1 |
| Scott Walcheck | 1 | 1 |
| Patrick Caruana | 1 | 1 |
| BERT VAN DEN BERGH | 1 | 1 |
| GREG ARCHAMBEAU | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.